

## Premature termination of a Clinical Trial

**Full title of the clinical Trial:**

A PILOT STUDY INVESTIGATING THE EFFECTS OF LIPID-THERAPY INTENSIFICATION WITH ALIROCUMAB ON ENDOTHELIAL FUNCTION, CAROTID ARTERIES, LIPOPROTEIN PARTICLE SUBFRACTIONS, INFLAMMATION AND POST-PRANDIAL LIPEMIA IN CLINICAL ROUTINE

**EudraCT Number:** 2018-000981-12

**Sponsor:** Medical University of Graz

**Represented by (name):** Assoz. Prof. Priv.-Doz. Dr.med.univ.et scient.med. Günther Silbernagel

**Reason for premature termination of the clinical trial:**

The clinical trial had to be prematurely terminated on the 03 April 2020 because of COVID-19 measures.

**Study results (if available):**

The clinical trial results were published in January 2022 as Open Access format:

- A. Short-Term Treatment with Alirocumab, Flow-Dependent Dilatation of the Brachial Artery and Use of Magnetic Resonance Diffusion Tensor Imaging to Evaluate Vascular Structure: An Exploratory Pilot Study, T. Metzner, D.R. Leitner, G. Dimsity, F. Gunzer, P. Opriessnig, K. Mellitzer, A. Beck, H. Sourij, T. Stojakovic, H. Deutschmann, W. März, U. Landmesser, M. Brodmann, G. Reishofer, H. Scharnagl, H. Toplak, and G. Silbernagel; Biomedicines 2022, 10, 152; <https://doi.org/10.3390/biomedicines10010152>, published: 11 January 2022; Open Access.
- B. Effects of Alirocumab on Triglyceride Metabolism: A Fat-Tolerance Test and Nuclear Magnetic Resonance Spectroscopy Study, T. Metzner, D.R. Leitner, K. Mellitzer, A. Beck, H. Sourij, T. Stojakovic, G. Reishofer, W. März, U. Landmesser, H. Scharnagl, H. Toplak, and G. Silbernagel; Biomedicines 2022, 10, 193. <https://doi.org/10.3390/biomedicines10010193>, published: 17 January 2022; Open Access.

**Date and Signature of Sponsor representative:**

Feb 3<sup>rd</sup>, 2022

  
Günther Silbernagel